Carl Zeiss Meditec


Sales acceleration and robust margin expansion in Q3

12/08/19 -"Sales momentum accelerated significantly in Q3 led by broad-based growth across the ophthalmology segment, particularly in Asia. Growth in adjusted EBIT was even higher on the back of the increasing ..."

Pages
48
Language
English
Published on
12/08/19
You may also be interested by these reports :
15/11/19
Sartorius Stedim reported solid Q3 19 results. Sales were up 16.4%, on a cc basis, while EBITDA came in at €110.2m (margin +140bp). Following the ...

15/11/19
According to market rumours, US MedTech giant, Thermo Fisher, has mulled over a bid on Qiagen. While the transaction value isn’t available yet, ...

15/11/19
Along with the increase in NAV, we have added Coloplast to our peer-based valuation, considering that the Danish MedTech firm’s top-line growth ...

11/11/19
Sales in Q3 were strong, led by broad-based growth across regions and channels in the Hearing and Audio segments. But, the EBITA margin was down 10bp ...

EXECUTIVE SUMMARY

Updates Pension Risks
Target & Opinion Governance & Management
Business & Trends Graphics : Momentum
Money Making Graphics : MACD & Volumes
Debt Graphics : Sensitivities
Valuation Sector: Performance
DCF Sector: Key data
NAV/SOTP Sector: Ratios & Valorisation
Worth knowing Sector: Peers
Financials Sector: Analysis

CONFLICTS OF INTEREST

AlphaValue does not have nor seek any business with companies covered in AlphaValue Research paid by subscription. As a result, investors can be confident that there is no conflict of interest that could affect the objectivity of AlphaValue Research.

Corporate broking NO
Trading in corporate shares NO
Analyst ownership NO
Advising of corporate (strategy, marketing, debt, etc) NO
Research paid for by corporate NO
Provision of corporate access paid for by corporate NO
Link between and a banking entity NO
Brokerage activity at AlphaValue NO